# Sorafenib in Newly Diagnosed High Grade Glioma

> **NCT00884416** · PHASE1 · COMPLETED · sponsor: **University Hospital, Geneva** · enrollment: 17 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma
- Anaplastic Astrocytoma
- Anaplastic Oligoastrocytoma
- Anaplastic Oligodendroglioma

## Interventions

- **DRUG:** Sorafenib dose escalation

## Key facts

- **NCT ID:** NCT00884416
- **Lead sponsor:** University Hospital, Geneva
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-12
- **Final completion:** 2012-03
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2014-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00884416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00884416, "Sorafenib in Newly Diagnosed High Grade Glioma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00884416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*